PDCD4 and non-small cell lung carcinoma: In this study, we found that the treatment of Trametinib was associated with a reduced level of miR-21 in both Osimertinib-resistant NSCLC cells (P_AZDR1 and H1975+CAF_R1) in the concert of increased expression of PDCD4.